EVENT SITE
WMIF MAIN SITE
Monday, June 12, 2023
9:45 AM - 10:30 AM
Watch Panel HereThis panel will take a focused look at the potential implications of the Inflation Reduction Act (IRA) of 2022 on biopharmaceutical innovation. While the full impact of the IRA is not yet clear, drug developers, patient advocates and other stakeholders are watching for the potential impact on small molecule drug development, on overall development of cancer therapies, on patient care for major chronic diseases, among other concerns.
Moderator
Tom Hubbard
Senior Vice President, Network for Excellence in Health Innovation (NEHI)
Panelists
Stephen Brady
CEO, Tempest Therapeutics
Remy Brim, PhD
Principal, BGR Group
Pat Fortune, PhD
Vice President, Strategic Innovation Leaders, Mass General Brigham Innovation
John Lepore, MD
SVP, Head of Research, GSK
© 2024 Mass General Brigham Incorporated. All Rights Reserved